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ABSTRACT: The molecular mechanisms by which different
proteins assemble into highly ordered fibrillar deposits and
cause disease remain topics of debate. Human amylin (also
known as islet amyloid polypeptide/hIAPP) is found in vivo as
amyloid deposits in the pancreatic islets of sufferers of type II
diabetes mellitus, and its self-aggregation is thought to be a
pathogenic factor in disease and to contribute to the failure of
islet transplants. Here, electrospray ionization-ion mobility
spectrometry-mass spectrometry (ESI-IMS-MS) has been used to monitor oligomer formation from IAPP. The detection,
identification and characterization of oligomers from both human and rat amylin (rIAPP) are described. Oligomers up to and
including hexamers have been detected for both peptides. From ESI-IMS-MS derived collision cross sections (CCS), these
species are shown to be elongated in conformation. Collision-induced dissociation (CID-MS/MS) revealed differences in the
gas-phase stability of the oligomers formed from hIAPP and rIAPP, which may contribute to their differences in amyloid
propensity. Using ESI-IMS-MS, the mode of inhibition of amyloid formation from hIAPP using small molecules or co-incubation
with rIAPP was also investigated. We show that the polyphenolic compounds epigallocatechin gallate (EGCG) and silibinin bind
to specific conformers within a dynamic ensemble of hIAPP monomers, altering the progress of oligomerization and fibril
assembly. Hetero-oligomer formation also occurs with rIAPP but leads only to inefficient inhibition. The results indicate that
although different small molecules can be effective inhibitors of hIAPP self-assembly, their modes of action are distinct and can
be distinguished using ESI-IMS-MS.
■ INTRODUCTION
Amyloid disorders are characterized by the aberrant aggregation
of proteins or peptides into amyloid fibrils.1 In each case,
normally soluble proteins or peptides that may be folded,
partially folded, or intrinsically disordered embark on alternative
aggregation energy landscapes2 leading to the formation of β-
sheet-rich fibrillar assemblies that can be characterized by the
binding of dyes such as Congo red or thioflavin T (ThT).3,4 The
identity of the toxic species associated with amyloid diseases is
widely debated as a result of the difficulty of separating,
identifying, and individually characterizing these heterogeneous
and transient intermediates of the assembly process.
Human islet amyloid polypeptide (hIAPP), also known as
amylin, is a highly amyloidogenic 37-residue peptide hormone
produced by the β-cells of the pancreas. It is produced, stored,
and co-secreted with insulin and plays a role in the control of
gastric emptying, glucose homeostasis, and suppression of
glucagon release.5,6 In its monomeric state, hIAPP is a soluble,
intrinsically disordered polypeptide but forms islet amyloid in
cases of type-2 diabetes mellitus (T2DM).5,7 Islet amyloid
formation leads to β-cell dysfunction, death, and reduction in β-
cell mass8,9 and contributes to the failure of islet cell
transplantation.5 Amyloid formation by IAPP is highly
sequence-specific.10 hIAPP forms amyloid readily at neutral
pH, while rat IAPP (rIAPP) does not, despite differing in
sequence at only six out of 37 amino acid positions (Figure 1a).
Significantly, five of these amino acid substitutions are located
within residues 20−29, three of which are Pro residues in rIAPP,
leading to supposed disruption of secondary structure
formation.11 Despite numerous studies on the conformational
properties, membrane binding, and aggregation of IAPP,5,10,12
important challenges remain in revealing the mechanism of
amyloid formation of hIAPP, particularly in the characterization
of oligomeric intermediates, which would enable detailed studies
of the mechanisms of assembly and the effects of known
inhibitors on the aggregation process.13,14
Most conventional biophysical techniques used in the study of
amyloid systems, including CD, FTIR spectroscopy, and
fluorescence-based assays, are limited to providing data relating
to a global average of species within heterogeneous mixtures.
Previous analytical ultracentrifugation studies,15 conducted at
pH 4.9 where aggregation is very slow, and 19F NMR studies16
have failed to detect low order oligomeric species for hIAPP,
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possibly due to the low population, or heterogeneous and/or
transient nature of such species. By contrast, photoinduced cross-
linking has identified oligomeric states, including monomer
through hexamer.17 Ion mobility spectrometry-mass spectrom-
etry (IMS-MS) has the unique advantage of being capable of
resolving complex mixtures of species present in solution,
including transiently populated states and even isobaric species
without requiring their prior separation.18−21 IMS-MS has been
utilized previously to provide insights into the oligomerization
pathways of other intrinsically unstructured amyloid-related
peptides and proteins including amyloid-β (Aβ) peptide20,22 and
α-synuclein,21,23 which are associated with Alzheimer’s disease
and Parkinson’s disease, respectively. In the case of Aβ40 and
Aβ42, oligomeric species up to and including 16-mer and 12-mer,
respectively, have been identified, and their rotationally averaged
collision cross-sectional areas (CCS) were measured using either
positive or negative ion IMS-MS.20,22 For α-synuclein, the
conformeric states of monomers were determined and the pH
dependence of dimer formation was demonstrated.23 IMS-MS
has also provided structural insights into the hIAPP monomer24
and dimer,25 as well as the self-assembly of a series of short
synthetic peptides derived from an amyloidogenic sequence
(20−29) of hIAPP.26 Using IMS-MS and replica-exchange
molecular dynamics (REMD) simulations, Dupuis et al.
proposed that full-length monomeric hIAPP occupies both a
helix−coil conformation and an extended β-hairpin conforma-
tion that has a significantly (18%) larger collision cross-section
(CCS).24 These extended hairpin structures were not observed
for rIAPP, leading to the conclusion that this conformer is an
amyloidogenic precursor. Dupuis et al. also investigated dimeric
structures of hIAPP, using IMS-MS, reporting that the dimers
observed are significantly more extended than those formed by
rIAPP, suggestive of a higher percentage of β-sheet content that
is formed from extended β-hairpin-containing monomers.25 An
early conformational transition to β-sheet-rich conformers was
proposed, therefore, as a first step in hIAPP self-assembly, by
contrast with other reports that have suggested a transition to
amyloid via helix-rich oligomers.27−29 None of these studies,
however, reported the detection or identification of higher order
species.
A wealth of studies has assessed the ability of small molecules
to interfere with the progress of fibril formation from many
amyloid-prone peptides and proteins in vitro.29−31 Despite these
analyses, the precise mechanisms of inhibition remain elusive.
Currently, there are no clinically approved inhibitors of hIAPP
assembly. In addition, the mode of action of small molecule
inhibitors of hIAPP aggregation is not well understood.
Electrospray ionization (ESI)-IMS-MS has been utilized
previously to identify inhibitors of β-2-microglobulin (β2m)
amyloid formation.32 Using a similar approach, we aimed here to
detect, identify, and characterize oligomeric intermediates of
hIAPP aassembly and, thereby, to determine the mode of action
of two known small molecule inhibitors of hIAPP amyloid
formation, epigallocatechin gallate (EGCG)33 and silibinin.34 In
addition, we used ESI-IMS-MS to investigate the moderately
effective inhibition caused by mixing hIAPP and rIAPP.11 EGCG
is one of the most effective amyloid inhibitors known35 and has
generated considerable attention given its ability to inhibit or
modulate amyloid formation from a diverse range of
polypeptides. Despite the plethora of these studies33,35−40 and
the interest they have generated, the mode of action of EGCG is
not well understood. It is thought to direct some, but not all,
amyloidogenic proteins into off-pathway aggregates.33,35
Here, using ESI-IMS-MS, we demonstrate the presence of
high order oligomers formed by both hIAPP and rIAPP and use
this technique to determine the populations, shapes, and gas-
phase stabilities of these co-populated, transient species. The
results reveal significant differences in the stability of otherwise
similarly organized oligomers of these peptides. In addition, the
binding of the small molecule inhibitors, EGCG and silibinin, to
specific conformers within the dynamic ensemble of hIAPP
species has also been ascertained, and the progress of oligomer
formation and fibril assembly and disassembly was monitored.
The results indicate that ligand binding either arrests
oligomerization (silibinin) or diverts hIAPP onto new assembly
routes resulting in the formation of amorphous aggregates
without a buildup of oligomeric species (EGCG). The results
presented provide evidence for the mode of action of these two
effective small molecule inhibitors of hIAPP amyloid formation
and reveal why rIAPP is such a poor inhibitor of hIAPP assembly.
■ EXPERIMENTAL SECTION
Sample Preparation for MS. hIAPP and rIAPP were synthesized
and purified as described previously.41 Lyophilized peptide samples
were dissolved in dimethyl sulfoxide (DMSO) at a final concentration of
peptide of 5 mM. After 24 h of incubation at 25 °C, stock solutions were
diluted 100-fold into 20 mM ammonium acetate, pH 6.8, to a final
peptide concentration of 50 μM forMS analysis. The final concentration
of DMSO was 1% (v/v). All samples were incubated at 37 °C in 96-well
plates with or without agitation (600 rpm). Experiments were repeated
at a range of IAPP concentrations, from 10 μM to 100 μM. As expected,
there is a concentration-dependence of the rate of fibril formation and
oligomer consumption as measured using ESI-IMS-MS. However, the
oligomers formed are of the same mass and CCS under each condition.
Figure 1. hIAPP forms an array of oligomeric species during fibril
formation. (a) Comparison of hIAPP and rIAPP sequences. Both
peptides have a disulfide bridge between Cys-2 and Cys-7 and have an
amidated C-terminus. Residues that differ from those of the human
peptide are colored pink in the rat sequence. (b) ESI-IMS-MS driftscope
plot of the hIAPP oligomers present 2min after diluting themonomer to
a final peptide concentration of 50 μM in 20 mM ammonium acetate,
pH 6.8, 37 °C, 600 rpm. ESI-IMS-MS driftscope plots show IMS drift
time versus m/z versus intensity (z = square root scale), and the
corresponding mass spectrum is shown on the left-hand side. Numbers
adjacent to peaks denote oligomer order, with the positive charge state
of each oligomer ions in superscript. The ESI mass spectrum shows the
2+ and 3+ charge state ions of hIAPP monomer (labeled 1) and minor
amounts of dimer and trimer (labeled 2 and 3, respectively).
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ESI-(IMS)-MS Analysis. A Synapt HDMS quadrupole time-of-flight
mass spectrometer (Micromass UK Ltd., Waters Corpn., Manchester,
U.K.), equipped with a Triversa (Advion Biosciences, Ithaca, NY, U.S.)
automated nano-ESI interface, was used for these analyses. Positive ion
mode was chosen because IAPP has a pI of >9 and therefore should be
predominantly positively charged at near-neutral pH. The instrument
has a traveling-wave IMS device situated in-between the quadrupole and
the time-of-flight analyzers and has been described in detail elsewhere.42
Samples were analyzed by positive ionization nanoESI (nESI) with a
capillary voltage of 1.7 kV and a nitrogen nebulizing gas pressure of 0.8
psi. The following instrumental parameters were used: cone voltage 30−
100 V; source temperature 60 °C; backing pressure 4.0 mBar; ramped
traveling wave height 7−20 V; traveling wave speed 400 m/s; IMS
nitrogen gas flow 20 mL/min; IMS cell pressure 0.55 mBar. The cone
voltage was optimized to transmit the higher order peptide oligomers;
the CCS of the oligomers did not alter over the range 30−100 V. Data
were processed by use of MassLynx v4.1 and Driftscope software
supplied with the mass spectrometer. The m/z scale was calibrated with
aq CsI cluster ions. CCSs were estimated by use of an IMS-MS
calibration.43 Calibration of the drift time cross-section function was
achieved by analysis of the denatured proteins equine cytochrome c and
horse heart myoglobin (10 μM in 50:40:10, v/v/v, acetonitrile/water/
acetic acid44), whose CCS values had been predetermined elsewhere by
use of conventional ion mobility measurements.44
The collision cross-sectional areas (Ω) of the analytes were then
obtained after calibration from their corrected drift times according to
eq 1:43
Ω = × ′ × × +A t z
m m
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ion gas (1)
This step also includes an adjustment for the mass and charge of the
protein ions, where Ω is the calibrated collision cross-section, A is the
calibration determined constant, tD′ is the absolute drift time
(corrected), z is the charge state of the ion, mion is the mass of the
ion, and mgas is the mass of the target gas used in the IMS cell. The
exponential factor B is determined experimentally.43
Collision induced dissociation (CID) MS/MS experiments were
performed using the quadrupole analyzer to select isobaric m/z ions
representing the dimer and tetramer, separating these ions in the IMS
device and performing CID in the transfer collision cell prior to the time-
of-flight analyzer (the pressure in the collision cell was kept constant).
Increasing collision energy was applied to the transfer collision cell in 10
V increments from 10 to 100 V until the oligomers ions were completely
dissociated into monomer ions. CID energies are displayed as center of
mass energy (eV) by use of the eq 2:
= ×
+
⎛
⎝
⎜⎜
⎞
⎠
⎟⎟E zE
M
M Mcent MS
argon
argon ion (2)
where z is the charge state of the ion, EMS is the collision energy used
(eV),Margon is the mass of argon the collision gas, andMion is the mass of
the analyte of interest. Note that the equation is missing a multiplication
factor of e, elementary charge (1.602 × 10−19 C). This has been omitted
as conversion of the zeVMS from Joules to electron volts is facilitated by
division of e.
Fibril Depolymerization. A mixed sample containing a 1:1 molar
ratio of hIAPP:rIAPP was prepared by diluting 5 mM stock solutions of
each peptide in DMSO 100-fold into 20 mM ammonium acetate, pH
6.8, to a final concentration of each peptide of 50 μM in 1% (v/v)
DMSO forMS analysis. After 5 days of incubation at 37 °C and 600 rpm,
mixed samples were centrifuged in a Beckman ultracentrifuge at
300,000g for 45 min. Fibrillar samples in the pellet were depolymerized
by incubation in 100% (v/v) HFIP for 24 h. Samples were air-dried and
then redissolved in 50:40:10 (v/v/v) acetonitrile/water/acetic acid, and
fibril constituent peptides were identified by ESI-MS.
Analysis of Ligand Binding to Monomeric hIAPP. hIAPP (50
μM) was dissolved in 20 mM ammonium acetate (pH 6.8) containing 5,
50, or 500 μM EGCG or silibinin in 1% (v/v) DMSO. For analysis of
these samples by nESI-MS, a sampling cone voltage of 30 V was used to
preserve protein−ligand interactions, and a backing pressure of 3.0 mbar
was applied. Data were acquired over the range m/z 400−8,000. For
IMS-MS experiments, the wave height was ramped from 7 to 20 V at a
speed of 300 m/s.
Thioflavin T Fluorescence Assays. Samples were prepared in a 96-
well plate (Corning Costar 3915, Corning Life Sciences, Amsterdam,
The Netherlands) sealed with clear sealing film and were incubated in a
FLUOstar OPTIMA plate reader (BMG Labtech, Aylesbury, Bucks,
U.K.) for 5 days at 37 °C with or without agitation (600 rpm). Samples
had a volume of 100 μL containing 100 μM ThT and 50 μM peptide in
20mM ammonium acetate, pH 6.8 and a 1% (v/v) final concentration of
DMSO. Fluorescence was excited at 440 nm, and emission intensity was
measured at 485 nm. Turbidity measurements were performed by
monitoring the apparent absorbance at 635 nm using a NEPHALOstar
Galaxy reader (BMG Labtech, Aylesbury, Bucks, UK) and 96-well clear
plates sealed with clear sealing film. For these experiments, the samples
were prepared as described above, except that ThT was not included. In
each experiment readings were taken every 5 min, from 2min to 50 h. In
parallel, samples were analyzed at different time points (but in the
absence of ThT) using ESI-IMS-MS. Each experiment under each
condition was repeated a minimum of three times with at least triplicate
measurements for each condition, and representative traces are shown.
Transmission Electron Microscopy (TEM). The TEM images of
each 50 μM peptide solution were acquired after 5 days of incubation at
37 °C on a CM10 microscope (Phillips, Electron Optics, Amsterdam,
The Netherlands). Carbon grids were prepared by irradiating under UV
light for 30 min and stained with 4% (w/v) uranyl acetate solution as
described previously.45
■ RESULTS
hIAPP Forms an Array of Oligomers Early in Amyloid
Assembly. To understand the aggregation process of amyloid-
prone peptides and proteins, oligomeric intermediates need to be
identified and characterized in detail. Here, by exploiting the
separative and investigative powers of MS coupled with IMS and
CID-MS/MS, we describe higher order oligomeric states
populated by hIAPP and rIAPP and elucidate their CCS, growth
mechanism, and relative gas-phase stability. The rat and human
peptides were each dissolved in 100% DMSO to remove any
preformed aggregates46 and diluted 100-fold into 20 mM
ammonium acetate, pH 6.8, and the distribution of oligomeric
species was analyzed immediately and at various time points after
dilution, using ESI-IMS-MS. The data obtained (Figure 1b)
showed that oligomers up to and including hexamers are formed
within 2 min of dilution of hIAPP into buffer. ESI-IMS-MS
allows co-populated oligomeric ions with the same m/z to be
separated and identified individually (e.g., dimer3+ and
tetramer6+) (Figure 1b). Multiple charge states, predominantly
doubly and triply charged, and different conformers, both
compact and expanded for species of the samemass, are observed
for the hIAPP monomer at this pH. For example, the monomer
2+ ions occupy two distinct peaks in the IMS-MS spectrum
(Figure 1b) with drift times of 7.6 and 10.6 ms. These represent
two conformations of this charge state, which have CCSs that
differ by a significant ∼15%. Although less well-resolved, the
monomer 3+ ions also exhibit two distinct conformations, having
drift times of 6.0 and 8.0 ms, a ∼14% difference in their CCS
(Figure 1b). Oligomers of hIAPP also populate a range of charge
states and conformations, for each of which the CCS was
determined (Supporting Information, Table 1).
Previous studies have shown that increased ionic strength
increases the rate of aggregation of many proteins and peptides,
including hIAPP.47 To investigate whether the presence of
oligomers of hIAPP correlates with the ability of the peptide to
assemble into amyloid fibrils, the ionic-strength dependency of
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the oligomers of hIAPP observed using ESI-IMS-MS was
investigated and compared with the rate of fibril formation,
measured using ThT fluorescence. Under the conditions
employed, an enhanced rate of amyloid formation is observed
as the ionic strength is increased from 20 to 500 mM, consistent
with previous studies47 (Figure 2a). Gross fibril morphology was
unchanged with the buffer conditions employed (a representa-
tive TEM image is shown (Figure 2b)). A more rapid decrease in
oligomer signal intensity over time was also detected with
increasing ionic strength (using ESI-IMS-MS, Figure 2c),
Figure 2. Dependence of hIAPP oligomer and fibril formation on ionic strength. (a) ThT fluorescence intensity of hIAPP (50 μM peptide, 37 °C, 600
rpm) in 20 mM (squares/purple), 100 mM (triangles/orange), or 500 mM (circles/green) ammonium acetate buffer, pH 6.8. (b) Representative
negative stain TEM image of hIAPP fibrils after 5 days in 100 mM buffer (37 °C, 600 rpm) (scale bar = 100 nm). (c) ESI-IMS-MS driftscope plots of
hIAPP oligomers present at t = 2 min (left-hand side) and t = 5 h (right-hand side) at different ionic strengths (20, 100, and 500 mM). (d) CCSs of
hIAPP oligomers measured using ESI-IMS-MS plotted versus oligomer order showing that oligomers have the sameCCS regardless of ionic strength: 20
mM (squares), 100 mM (triangles), and 500 mM (circles). The orange dashed line represents a globular fit based on the average density of a protein
(0.44 Da/Å3),49 the purple dashed line represents a linear growth model,48 and the green dashed line represents an isotropic growth model.48
Figure 3.Oligomers formed from rIAPP resemble those of hIAPP. (a) ESI-IMS-MS driftscope plot of rIAPP oligomers present at 2 min after dilution
into 20mM ammonium acetate buffer, pH 6.8 to a final peptide concentration of 50 μM. The number adjacent to each peak denotes oligomer order with
charge state of the oligomer in superscript. (b) Aggregation of rIAPP (diamonds) and hIAPP (circles) monitored using turbidity at 635 nm. In both
cases, 50 μM peptide was incubated in 20 mM ammonium acetate buffer, pH 6.8 (37 °C, 600 rpm). (c) Negative stain TEM image of rIAPP aggregates
after 5 days of incubation (37 °C, 600 rpm); scale bar = 100 nm. (d) ThT fluorescence intensity of rIAPP (50 μMpeptide, 37 °C, pH 6.8, 600 rpm). The
data are normalized to the signal intensity of a hIAPP fibril formation end point at the same peptide concentration.
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consistent with the oligomers observed being involved in
assembly into amyloid.
To probe the properties of the oligomers formed from hIAPP
in more detail, their CCSs were estimated from the ESI-IMS-MS
arrival time distributions and compared with CCSs estimated for
theoretical models including a fit assuming isotropic growth,48 a
globular fit based on the average density of a protein under
similar conditions (0.44 Da/Å3),49,50 and a model that assumes
growth in a single dimension48 (note that more detailed
molecular models cannot be generated for the underlying
structures of the oligomers detected, given the lack of
information about the type, location, or extent of secondary
structure in these species). CCS determination (Experimental
Section) suggests that hIAPP oligomers ≥4-mer in size adopt an
extended conformation and that the CCS of the different
oligomers observed are independent of ionic strength (Figure
2d). However, the relative population of compact vs expanded
monomeric and dimeric conformers is altered with increasing
ionic strength (discussed below).
CID Reveals Differences in Gas-Phase Stability be-
tween hIAPP and rIAPP Oligomers and Monomers. For
rIAPP, which does not form ordered amyloid fibrils when
incubated at near neutral pH,5 a surprisingly similar array of
oligomers was observed using ESI-IMS-MS compared with that
detected for hIAPP (Figure 3a, Supporting Information Figures
S1a and S2). Akin to the results observed for hIAPP, multiple
conformers are observed for rIAPP monomer and oligomers,
albeit at different relative intensities compared with those
observed for hIAPP. Accordingly, hIAPP consistently occupies a
greater proportion of more expanded conformers than rIAPP
(Supporting Information Figure S1b). To investigate the relative
stabilities of the different monomeric conformers of hIAPP and
rIAPP, the dependence of the ion arrival time distribution versus
increasing the trap energy (used to effect CID) was examined
(Supporting Information, Figure S1c). The results of these
experiments showed that hIAPP monomer 3+ ions unfold at
lower trap collision energies than those required for the rIAPP
monomer, with hIAPP more readily converting to expanded
conformers at lower trap voltages (Supporting Information
Figure S1c).
Although rIAPP has been reported previously not to form
amyloid fibrils,5 turbidity measurements (Figure 3b) and TEM
images (Figure 3c) showed that under the conditions employed
here (20 mM ammonium acetate, pH 6.8, 1% DMSO (v/v)),
rIAPP forms small globular aggregates that scatter light but do
not bind ThT (Figure 3d). The rIAPP oligomers observed are
similar in CCS, as well as order and mass, to those of hIAPP
(Supporting Information Table S1 and Figures S1a and S3).
These results indicate, therefore, that the presence of oligomers
of similar numbers of subunits and CCS cannot account for the
very different amyloidogenic properties of the two sequences.
Next, the gas-phase stabilities of oligomers of hIAPP and
rIAPP were probed to investigate whether their gas-phase
dissociation can be related to the differences in the ability of these
sequences to form amyloid. These oligomers are not amenable to
solution-phase stability assays, since they are so lowly populated
and co-populated with each other and the monomeric species.
Accordingly, CID-MS/MS was utilized to provide a side-by-side
comparison of the gas-phase stabilities of the two peptides in
different oligomeric forms. In this experiment, ions of specificm/
z were selected by the quadrupole analyzer, followed by IMS
separation of the different oligomers contributing to thism/z and
then sequential fragmentation of the oligomer ions in the transfer
collision cell immediately prior to the time-of-flight analyzer. The
data revealed that hIAPP dimers are significantly less stable than
rIAPP dimers in the gas phase. hIAPP dimers were found to
dissociate into monomer at an energy (0.4 eV) that is lower than
that required for the equivalent rIAPP dimers, which only began
to dissociate at 0.7 eV (Figure 4a). Oligomeric species, including
tetramer ions with six charges, also showed subtle differences in
stability for the two sequences. The hIAPP tetramer6+ ions begin
to dissociate at 0.3 eV, whereas rat tetramer6+ ions remain fully
associated until an energy of 0.5 eV is applied (Supporting
Information Figure S4a,b). The significant difference in the gas-
phase stability of the dimer ions of hIAPP and rIAPP could be
related to the capability of hIAPP to access amyloidogenic
conformations more easily than its rIAPP counterpart.
Consistent with this view, the expanded conformers of the
Figure 4. Differences between rIAPP and hIAPP dimer and monomer
stabilities in the gas phase measured using collision induced dissociation
(CID). (a) CID MS/MS of rIAPP (blue) and hIAPP (red) dimers (50
μM peptide, 20 mM ammonium acetate buffer, pH 6.8). Relative
intensity of the 3+ dimer ions (squares) of each peptide is plotted versus
increasing ion-accelerating voltage into the transfer T-wave collision cell
(CID). Monomer ion intensity (diamonds) increases as dimers
(squares) dissociate. Bar chart (inset) showing the appearance of
hIAPP (red) and rIAPP (blue) monomer from dissociation of dimer
ions with increasing CID voltage. (b) Arrival time distributions (ATDs)
of 3+ hIAPP monomer ions 2 min after dissolving into 50 mM (purple),
100 mM (orange), or 500 mM (green) ammonium acetate, pH 6.8. Bar
chart (inset) showing relative intensity of monomer ions with increasing
ion-accelerating voltage at different ionic strengths: 50 mM (green), 100
mM (orange), and 500 mM (purple) (25 μMpeptide, 50/100/500 mM
ammonium acetate buffer, pH 6.8).
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hIAPP monomer and dimer ions became increased in
population, and the dimer 3+ ions become less stable in the
gas phase as the ionic strength of the buffer used is increased
(Figure 4b). This supports the hypothesis that peptide gas-phase
stability is inversely correlated with the amyloid competence of
IAPP, given that both the hIAPP monomer and its oligomers are
less stable than their counterparts for the rat sequence and that
high ionic strength destabilizes oligomers and increases the rate
of amyloid fibril formation for hIAPP.
Probing the Mechanism of Inhibition of hIAPP Fibril
Formation with Small Molecules. Having identified the
prefibrillar species populated by hIAPP, the mode of action of
two known small molecule inhibitors of hIAPP fibril formation
was investigated using ESI-IMS-MS. In these experiments,
hIAPP (50 μM) was incubated at 37 °C in 20 mM ammonium
acetate buffer, pH 6.8, in the presence of EGCG33,35 or silibinin34
at molar ratios of small molecule:hIAPP of 0.1:1, 1:1, or 10:1.
The oligomer populations were characterized subsequently using
ESI-IMS-MS. To complement the gas-phase analyses, fibril
formation was monitored by ThT fluorescence, and peptide
aggregates were characterized using negative stain EM. The
primary objectives here were to determine how the presence (or
binding) of each small molecule affects the distribution of
monomeric conformers and populations of oligomers and
whether such changes can be correlated with the inhibition of
hIAPP amyloid formation.
1. Action of EGCG on Fibril Formation of hIAPP Probed by
ESI-IMS-MS. EGCG, a polyphenol flavanol found in green tea,
has shown promise as a generic anti-amyloid agent as this small
molecule has been found to redirect aggregating proteins onto
alternative pathways35 or to maintain them in a native-like
state.37 It has also been shown to promote remodeling of mature
amyloid fibrils,33 with recent work of Kelly et al. demonstrating
that hydrophobic binding to the amyloid fibril by EGCG is a
significant step in this process.40 Despite being proposed as a
potent inhibitor of amyloid formation for several proteins and
peptides including hIAPP,36 α-synuclein, and Aβ42,
35 the mode
of action of EGCG remains elusive. To identify the effects of
EGCG on hIAPP aggregation, the binding capabilities of
individual monomeric conformers of hIAPP for EGCG were
investigated. The results revealed that EGCG binds to
monomeric hIAPP (∼10% monomer remains bound in the gas
phase) (Figure 5a) (note that estimating Kd values of binding
events by MS was not feasible in this instance, given the difficulty
of maintaining quantitative amounts of bound ligand in the gas
phase). The presence of the small molecule also alters the
equilibrium of monomer charge states present. Themonomer 3+
ions are more highly populated in samples incubated with EGCG
(compare Figures 1b and 5a), with a change in ratio of 3+:2+
monomer charge states in the spectra changing from ∼1:2 to
∼1:1.2 in the presence of the ligand. It is possible that the
changes inmonomer charge state distribution observedmay arise
from direct binding of EGCG to the monomer that causes
conformational changes and hence alters the profile of the charge
state distribution, despite the ligand dissociating in the gas phase.
Alternatively, changes in the charge state distribution may arise
from gas-phase dissociation of ligand-bound higher order
oligomeric species. In addition to its effects on the monomeric
conformers of hIAPP, EGCG binding inhibits assembly of the
peptide into higher order oligomers and fibrils (Figure 5b−d).
Both of the observed charge states (2+ and 3+) of the hIAPP
monomer (Figure 5a) and indeed each monomeric conformer
(both the expanded and the compact form of each charge state)
(Supporting Information Figure S5) are bound by EGCG, with
one or two molecules binding to one doubly charged monomer
and up to three EGCG molecules binding to the triply charged
Figure 5. Inhibition of hIAPP fibril formation by EGCG. (a) Positive ion ESI mass spectrum showing binding of EGCG (added at 500 μM to 50 μM
peptide) to both the 2+ (orange) and 3+ (purple) charge state ions of hIAPP monomer. Stoichiometry of binding is shown by color: 1:1 inhibitor
molecule bound to an IAPPmonomer is highlighted in green, 2:1 in pink, and 3:1 in blue. EGCG is shown as an inset. (b) ThT fluorescence intensity of
hIAPP (black) (50 μMpeptide, 20mM ammonium acetate buffer, pH 6.8, 37 °C, 600 rpm) with increasing EGCG:hIAPPmolar ratios: 0.1:1 (pink), 1:1
(orange), and 10:1 (blue). (c) ESI-IMS-MS driftscope plots of hIAPP oligomers formed in the presence of (i) 0.1:1, (ii) 1:1, and (iii) 10:1molar ratios of
EGCG:peptide monomer at t = 5 h. The number of EGCGmolecules bound to each species is shown as a colored dot. (d) Negative stain TEM images of
hIAPP incubated with (i) 0.1:1, (ii) 1:1, and (iii) 10:1 molar ratios of EGCG for 5 days (37 °C, 600 rpm). (iv) hIAPP fibrils alone and aggregates formed
when a 10-fold molar excess of EGCG:hIAPP is added to preformed hIAPP fibrils after 5 h (v) and 24 h (vi). Scale bar is 100 nm.
Journal of the American Chemical Society Article
dx.doi.org/10.1021/ja406831n | J. Am. Chem. Soc. 2014, 136, 660−670665
monomer when EGCG is added in an 10-fold molar excess over
hIAPP (Figure 5a). Binding of EGCG to both the 2+ and 3+
monomer ions was also observed at a stoichiometry of 1:1
hIAPP:EGCG, albeit at a lower intensity (data not shown). The
low levels of binding observed, despite complete inhibition of
fibrillation, are consistent with hydrophobic interactions playing
a role in the binding interface36 and may help toward explaining
the ability of EGCG to inhibit a wide range of natively unfolded
polypeptides, including IAPP mutants.37,38
ESI-IMS-MS data (Figure 5c) reveal that incubation with
increasing molar ratios of EGCG:hIAPP prevents the appearance
of higher order oligomers in a dose-dependent manner. At 0.1:1
and 1:1 molar ratios of EGCG:hIAPP, monomer through
tetramer species of hIAPP are observed (Figure 5c), but no
pentamer or hexamer (which were observed in the absence of the
small molecule (Figure 1b)). At a 10:1 molar ratio of
EGCG:hIAPP, no oligomers are observed (Figure 5c). Under
the latter conditions, there is no increase in ThT fluorescence
(Figure 5b), and TEM images (Figure 5d, panel iii) do not show
any aggregated material, indicating complete inhibition of
amorphous aggregate and amyloid formation. These results
suggest that EGCG may trap amyloidogenic oligomers as low
order species and differentially stabilize distinct monomeric
charge states of hIAPP with the result that amyloid fibrils cannot
form. Alternatively, EGCG may divert low order oligomers of
hIAPP onto other aggregation pathways that result in the
formation of aggregates that are incapable of forming amyloid. In
the latter scenario, the oligomers that form must be of low
abundance, low ionization propensity, or too heterogeneous to
be detected by ESI-IMS-MS.
Remodeling of Mature IAPP Fibrils by EGCG. In addition
to its ability to remodel oligomers,35 EGCG has been shown
previously to remodel amyloid fibrils formed by a range of
polypeptides, including hIAPP.35,36 Having determined the effect
of EGCG on the aggregation reaction of hIAPP, the effect of this
small molecule on fibril depolymerization was studied also, using
TEM to monitor fibril loss and ESI-IMS-MS to investigate how
fibril remodeling by EGCG influences oligomer populations.
Fibril samples formed by incubation of hIAPP at pH 6.8 for 5
days were mixed with a 10-fold molar excess of EGCG, and the
subsequent loss of fibrils was monitored by TEM and ESI-IMS-
MS at various time points after addition of the small molecule.
The results of these experiments are shown in Figure 5d (panels
iv−vi) and in Supplementary Figure S6a. Under the conditions
employed, clumping of hIAPP fibrils followed by remodeling
into amorphous aggregates over a 24 h period was observed
(Figure 5d, panels iv−vi). This is accompanied by a subtle
increase in intensity of the signal arising from monomer ions,
measured using ESI-IMS-MS, compared with the same sample
prior to addition of EGCG (Supporting Information Figure S6a).
There is, however, an absence of higher order oligomers
indicating that fibril remodeling by EGCG does not result in
the reformation of higher order oligomeric species.
2. Action of Silibinin on Fibril Formation of hIAPP Probed by
ESI-IMS-MS. Silibinin, a flavonol extracted from seeds of the herb
milk thistle, has been proposed as a potential therapeutic for
Figure 6. Inhibition of hIAPP fibril formation by silibinin. (a) Positive ion ESI mass spectra showing binding of silibinin molecules (added at 500 μM to
50 μM peptide) to the 3+ monomer ions (purple) and absence of binding to the 2+ monomer ions (orange) at a molar ratio of silibinin:hIAPP of 10:1.
The structure of silibinin is inset. (b) ESI-IMS-MS driftscope plots showing the lack of hIAPP oligomers in the presence of 0.1:1, 1:1, and 10:1 molar
ratios of silibinin:hIAPP at t = 5 h. (c) Arrival time distribution of 3+ monomer ions shows two conformers are present (tD = 6 and 8 ms). Silibinin binds
to the extended conformer of the 3+monomer ions (pink) but does not bind to the compact conformer (blue). (d) ThT fluorescence intensity of hIAPP
(black) (50 μM peptide, 20 mM ammonium acetate buffer, pH 6.8, 37 °C, 600 rpm) with increasing silibinin:hIAPP molar ratios: 0.1:1 (pink), 1:1
(orange), and 10:1 (blue). (e) Negative stain TEM images of hIAPP incubated with (i) 0.1:1, (ii) 1:1, and (iii) 10:1 molar ratios of silibinin:hIAPP for 5
days (37 °C, 600 rpm). Lower panels show hIAPP fibrils alone (iv) and aggregates formed when a 10-fold molar excess of silibinin:hIAPP is added to
preformed hIAPP fibrils after 5 h (v) and 24 h (vi). Scale bar is 100 nm.
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amyloidosis associated with T2DM.34 The interaction of this
inhibitor with hIAPP was also probed using ESI-IMS-MS. The
resulting data (Figure 6a) revealed that silibinin binds to the 3+
charge state ions of monomeric hIAPP (∼20% remaining bound
in the gas phase), with no detectable binding to the 2+ charge
state ions of the monomer. This may be due to selectivity of the
small molecule or the low abundance of the 2+ charge state in the
presence of the small molecule. In the latter case, the intensity of
ligand-bound ions may fall below the levels of detection. Like
EGCG, but more obviously, the presence of excess silibinin alters
the equilibrium of the two different charge states of monomeric
hIAPP, favoring the population of the triply charged monomer
ions, changing the ratio of 3+:2+ monomer charge state ions in
the spectra from∼1:2 without silibinin to∼3:1 in the presence of
the small molecule. In addition, analysis using ESI-IMS-MS
indicates that the presence of substoichiometric ratios of
silibinin:hIAPP prevents hIAPP oligomer formation (Figure
6b). More specifically, binding of silibinin is observed only to the
expanded conformer of the 3+ monomer ions (Figure 6c). This
conformer (CCS = ∼790 Å2), adopted by the hIAPP monomer,
but not the rIAPP monomer (Supporting Information Figure
S1b,ii), has been proposed previously as the on-pathway,
amyloid-competent conformation, the formation of which
precedes the generation of extended dimers and β-sheet-rich
oligomers.24,25 There is no detectable binding of silbinin to the
rIAPP monomer when incubated under identical conditions
(Supporting Information Figure S7). Specific binding to the
expanded monomer conformation of hIAPP is thus consistent
with the ability of silibinin to inhibit amyloid formation. ThT
data (Figure 6d) showed that aggregation of hIAPP decreases
significantly as the concentration of silibinin is increased,
although in a 10-fold molar excess of silibinin a weak positive
ThT signal is still observed (Figure 6d), likely due to the
presence of aggregates not visible by ESI-IMS-MS. TEM images
indicated that incubation of monomeric hIAPP with silibinin for
5 days leads to few aggregates, with none visible by TEM when a
10-fold molar excess of silibinin:hIAPP is used (Figure 6e, panels
i−iii).
Remodeling of Mature IAPP Fibrils by Silibinin.
Although silibinin has been shown previously to inhibit fibril
formation by hIAPP,34 the interaction of this small molecule with
preformed fibrils had not been reported. Preformed hIAPP fibrils
were incubated, therefore, with a 10-fold molar excess of silibinin,
and the effect of addition of the small molecule was measured
using TEM and ESI-IMS-MS. The results showed that addition
of silbinin causes depolymerization of preformed fibrils over a 24
h time period during which time fibrils decrease in length (Figure
6e, panels iv−vi). During fibril depolymerization, ESI-IMS-MS
revealed a simultaneous increase in low-order oligomeric species
(Supporting Information Figure S6b), suggesting that depoly-
merization may occur via oligomer release. Alternatively,
monomer release may occur and initiate rapid reformation of
oligomers in solution. Oligomers reformed upon fibril
depolymerization are comparable in CCS to those formed
during amyloid formation (data not shown).
Formation of Hetero-oligomers and Heterofibrils of
hIAPP and rIAPP. A range of peptide inhibitors has been
developed against hIAPP.51−54 However, the lack of structural
information available on the intermediates of aggregation has
made it difficult to rationalize why some are more effective than
others. Despite rIAPP having been used previously as the basis
for design of an FDA approved therapy to treat T2DM,55 this
peptide is only moderately effective in inhibiting hIAPP
aggregation when added at equimolar concentrations.11 A two-
dimensional infrared spectroscopy study revealed that rIAPP can
become amyloid-competent in the presence of hIAPP,
converting from a natively disordered rIAPP monomer into an
ordered β-sheet-rich complex with hIAPP.56 To determine why
the rIAPP peptide is an ineffective inhibitor of hIAPP assembly
and to identify how the hIAPP-rIAPP complex forms, ESI-IMS-
MS was used to study the oligomeric structures present in a
mixture (1:1 molar ratio) of the two peptides.
Figure 7. Lack of hIAPP inhibition by rIAPP. (a) ESI-IMS-MS driftscope plot of oligomers present at t = 2min in a mixed sample of hIAPP and rIAPP at
a 1:1 molar ratio (50 μM final peptide concentration, 20 mM ammonium acetate buffer, pH 6.8, 25 °C). Extracted driftscope peak shows masses
corresponding to a mixed dimer of one hIAPP monomer plus one rIAPP monomer (inset). (b) ThT fluorescence intensity during agitation of
hIAPP:rIAPP 1:1 (50 μM final peptide concentration, 20 mM ammonium acetate buffer, pH 6.8, 37 °C, 600 rpm). Data for three replicates are shown.
(c) Negative stain TEM image of 1:1 hIAPP: rIAPP fibrils after 5 days. Scale bar = 100 nm. (d) ESI mass spectra of depolymerized fibrils showing the
presence of both hIAPP and rIAPP monomer constituents in the pellet (i) and supernatant (ii) following ultracentrifugation.
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By contrast with the decrease in oligomer populations of
hIAPP observed in the presence of the two small molecule
inhibitors studied here, oligomers up to and including hexamer
were formed upon incubation of the hIAPP and rIAPP (Figure
7a), consistent with results observed when each peptide was
incubated in isolation. The presence of rIAPP did not prevent
fibril formation of hIAPP under the conditions of these
experiments (Figure 7b), consistent with previous reports
suggesting that the rat peptide must be present in an ∼10-fold
molar excess to inhibit hIAPP amyloid formation noticeably.11,56
The fibrils formed from the mixed sample were of similar
morphology to those of hIAPP incubated alone (Figure 7c).
Mixed oligomers were observed using ESI-IMS-MS with m/z
values corresponding to all-hIAPP, all-rIAPP, and oligomers
containing a mixture of hIAPP and rIAPP monomer subunits.
The triply charged dimer ions (Figure 7a, inset), for example,
have an m/z of 2608, corresponding to one hIAPP monomer
(3904 Da) and one rIAPP monomer (3921 Da), carrying three
positive charges. Mixed trimers and higher order oligomers were
observed also, as well as homo-oligomers of both peptides. The
ability to form mixed oligomers rationalizes why rIAPP is
inefficient at inhibiting hIAPP amyloid formation. After 5 days,
the fibrils formed were ultracentrifuged and depolymerized by
incubation in 100% HFIP for 24 h with agitation. Samples were
then air-dried and resuspended in denaturing solvent (50:40:10
acetonitrile/water/acetic acid (v/v/v)). The resulting mass
spectra (Figure 7d, panel i) showed the presence of both
hIAPP and rIAPP monomer subunits in the aggregate pellet,
confirming the presence of both peptides in the fibrillar state,
with approximately twice as many hIAPP monomer units being
incorporated into the fibrils compared with rIAPP monomers
under the conditions employed. Bothmonomers were also found
in the supernatant of the original mixed sample, with rIAPP
monomers being in excess here (Figure 7d, panel ii). The CID-
MS/MS method of interrogation of oligomer stability was used
to probe the stability of the mixed oligomers formed from hIAPP
and rIAPP by subjecting the heterodimer and heterotetramer
ions to increasing transfer collision cell voltages to promote gas-
phase dissociation. Interestingly, the hetero-oligomers exhibited
gas-phase stabilities between those of homo-oligomers of hIAPP
and rIAPP of the same mass, being less stable than rIAPP
oligomers but more stable than hIAPP oligomers (Supporting
Information Figure S8).
Taken together, therefore, the ESI-IMS-MS and CID-MS/MS
data suggest that differences in gas-phase stability of monomer
and low order oligomers between hIAPP and rIAPP sequences
could be related to their differences in amyloid propensity. In
addition, small molecule binding to hIAPP prevents fibril
formation by disfavoring oligomer formation via binding to
monomers. As a result, the aggregation pathway is diverted to
alternative routes that result in the formation of monomers and/
or amorphous aggregates.
■ DISCUSSION
Identifying and characterizing the structures and dynamics of
prefibrillar oligomers is vital for understanding the mechanisms
of protein aggregation in amyloid disease, identifying the specific
culprits of toxicity, and designing therapeutics to prevent
aggregation. Here, using ESI-IMS-MS, the high order oligomers
of hIAPP and rIAPP have been characterized for the first time,
and their structural organization and relative gas-phase stabilities
were compared. Additionally, the binding and mode of action of
two small molecule inhibitors of hIAPP have been determined,
and the relative ineffective inhibition of hIAPP by rIAPP has been
investigated. Previous IMS-MS studies into the structure of
hIAPP monomer and dimer have suggested that a conforma-
tional transition to an extended structure is likely as an early step
in amyloid formation.24,25 In the study presented here, the
population of monomer through hexamer has been revealed for
both peptides. These oligomers likely assemble via monomer
addition (since every species from monomer to hexamer is
observed). In the case of hIAPP, further monomer association
into higher order oligomers is not observed, suggesting that fibril
formation occurs without measurable population of larger
oligomeric intermediates or that higher order species are too
lowly populated, too transient, or too heterogeneous to be
detected by ESI-IMS-MS. The oligomeric states observedmay be
“on-pathway” to fibril formation or alternatively may be off-
pathway. In the latter case, conformational changes occurring
due to the oligomers’ relative lack of structural stability may
facilitate amyloid assembly compared with their counterparts in
rIAPP.
CCS estimations on hIAPP species indicate that the early
oligomers formed are elongated rather than globulamers, akin to
the oligomers observed during β2m assembly into amyloid.
50 Of
interest, early oligomers of rIAPP, which are similar in size and
CCS to those of hIAPP, are formed when the peptide is
incubated under conditions identical to those used to analyze
hIAPP but are significantly more stable in the gas phase as judged
by CID experiments. Although solution-phase stability cannot be
directly inferred from gas-phase stability,57,58 the difference in
stability observed may rationalize the difference in aggregation
propensity of the two peptides, assuming that a conformational
change is necessary for fibril formation that is impeded for the
more stable rat peptide. The ability of the two peptides to form
mixed oligomeric species on pathway to heterofibrils in vitro has
been revealed using ESI-IMS-MS and has provided an
explanation as to the inefficient inhibition of hIAPP amyloid
formation by rIAPP. The study highlights the pitfalls associated
with designing peptide inhibitors based on amino acid sequence,
given that rIAPP in principle would be expected to be a good
inhibitor of hIAPP since it combines a recognition motif with a β-
sheet breaker unit.11
Having characterized the oligomeric species of hIAPP, the
binding of two potent hIAPP amyloid inhibitors, EGCG and
silibinin, were studied using ESI-IMS-MS. Negative controls
were performed using molecules that do not have an inhibitory
effect on hIAPP amyloid formation (e.g., rifampicin59 and
benzimidazole); these do not to bind hIAPP or inhibit
oligomerization (data not shown). We show that both EGCG
and silibinin are able to block oligomer and fibril formation from
hIAPP when added prior to amyloid assembly, despite showing
different binding characteristics and having different effects on
the equilibrium of species present. By contrast with the
observations made at high ionic strength, in which oligomers
are formed and then lost from the ensemble rapidly as they
elongate into fibrils, the presence of these small molecules
inhibits formation of oligomeric species frommonomer subunits.
In both scenarios, the observation is the same (lack of persistence
of signal arising from oligomeric ions). However, the
interpretation of the molecular events that lead to the observed
absence of oligomeric species is fundamentally different. EGCG
was found to bind to both observed charge states of the hIAPP
monomer, inhibiting early oligomer formation in a dose-
dependent manner and preventing fibril formation. By contrast,
silibinin was detected to bind only to the most expanded
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conformer of themonomer 3+ ions within the dynamic ensemble
of intrinsically disordered monomeric conformations, blocking
oligomerization and fibrillation. The latter result supports the
notion of the role of the extended state of the monomer 3+
species in the fibril assembly mechanism of hIAPP because the
hIAPP conformer bound by silibinin is absent in rIAPP. Binding
to monomer may inhibit assembly directly or may create a
structure that associates with other monomers to generate non-
amyloidogenic aggregates. The fact that both EGCG and silibinin
were found to be effective as amyloid inhibitors at substoichio-
metric concentrations suggests that the small molecules may
bind to oligomers, as well as the monomer. Due to the low
intensity of oligomers in the presence of small molecules,
however, binding of small molecules to these species could not be
observed by ESI-IMS.
Both EGCG and silibinin alter the equilibrium of the
monomeric charge states of hIAPP present, with the addition
of each small molecule leading to increased population of the
triply charged monomer ions. We propose that binding to these
extended species prevents their self-assembly into amyloid.
Previous studies have shown that altering the equilibration
between different monomeric conformers can divert β2m to
alternative assembly pathways,32 leading to formation of
spherical aggregates rather than highly ordered β-sheet rich
fibrillar assemblies. For hIAPP, these alternative aggregation
pathways are presumably kinetically or thermodynamically
unfavorable in the absence of EGCG and silibinin but made
feasible upon ligand binding to unfolded hIAPP monomers. The
fact that both of these small molecules are capable of
disaggregating hIAPP amyloid fibrils in distinguishable manners
is also of interest. EGCG remodels fibrils into amorphous
aggregates without reformation of low order oligomers, while
silibinin depolymerizes fibrils and re-establishes the prefibrillar
array of monomer plus early oligomeric species observed by ESI-
IMS-MS.
It is widely accepted that early oligomeric states are key to
protein self-assembly and subsequent amyloid disease, and
determination of which species are on-pathway to amyloid
assembly is vital. Here we have used ESI-IMS-MS to show that
specific, lowly populated hIAPP monomeric conformers are
capable of binding small molecule ligands. In addition we have
used this technique to identify a range of extended oligomeric
assemblies. We have assessed the effect of ligand binding on each
individual species within a heterogeneous mixture of peptide
monomers and their conformers populated prior to fibril
formation. Our experimental results provide support for a
route to hIAPP amyloid fibrils via formation of elongated
oligomers. We propose that reduced stability (relative to
nonamyloidogenic rIAPP) is related to the ability of hIAPP to
form extended monomer and oligomeric conformations that
have increased amyloid propensity compared with their more
stable counterparts. Binding to and stabilizing monomers,
thereby preventing their polymerization, could be key to the
mechanism of inhibition of amyloid by EGCG and silibinin.
■ CONCLUSIONS
The data presented herein, and previously by Bowers and co-
workers,24,25 demonstrate that formation of extended structures
is likely key in early amylin amyloid formation. Small molecule
binding to these extended structures, which results in alteration
of the distribution of conformers present, leads to inhibition of
oligomerization and fibrillation by hIAPP. We hypothesize that
stability plays a role in the sequence specificity of IAPP amyloid
formation, given that oligomers of rIAPP (that differs at only six
amino acid positions compared with hIAPP) are similar in size
and shape to those of hIAPP but are significantly more stable in
the gas phase. In order for amyloid systems to be fully
understood, all species on the energy landscape, both “on-
pathway” and “off-pathway”, must be identified. We cannot
determine unequivocally whether the oligomers detected here
using MS are on- or off-pathway. Whichever scenario is correct,
our data are consistent with a lower stability corresponding to an
enhanced rate and/or ability to form amyloid fibrils. Oligomers
either may be on-pathway to fibril formation and require
conformational changes to progress assembly or alternatively
may undergo conformational changes allowing off-pathway
species to enter the aggregation pathway to amyloid. Addition-
ally, we demonstrate that the mixing of the hIAPP and rIAPP
sequences leads to copolymerization into amyloid, hence
explaining the lack of inhibition of hIAPP fibril formation by
rIAPP.
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